Financial momentum, breakthrough tech and global expansion are aligning.
After divesting its only commercial product, Seres Therapeutics is making a bold bet on its pipeline. Here's why that gamble might pay off.
Targeting MS repair, hangover relief, and alcohol detox - with the cash to execute through 2027.
$60 million in profit, earnings looming and a misunderstood valuation, investors may be missing the real story behind this healthcare disruptor’s next move.
